Lodenafil Carbonate | 398507-55-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Lodenafil Carbonate
• 英文别名: bis[2-[4-[4-ethoxy-3-(1-methyl-7-oxo-3-propyl-6H-pyrazolo[4,3-d]pyrimidin-5-yl)phenyl]sulfonylpiperazin-1-yl]ethyl] carbonate
• CAS: 398507-55-6
• 化学式: C₄₇H₆₂N₁₂O₁₁S₂
• 分子量: 1035.2
• InChiKey: MVYUCRDXZXLFSB-UHFFFAOYSA-N

物化性质

• 熔点：
  229-231°C
• 沸点：
  1109.0±75.0 °C(Predicted)
• 密度：
  1.47±0.1 g/cm3(Predicted)
• 溶解度：
  氯仿（微溶）、DMSO（微溶、加热）

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  72
• 可旋转键数：
  22
• 环数：
  8.0
• sp3杂化的碳原子比例：
  0.51
• 拓扑面积：
  271
• 氢给体数：
  2
• 氢受体数：
  17

文献信息

• COMPOSITIONS AND METHODS FOR LIPID METABOLISM DISORDER
  申请人：Jansfat Biotechnology Co., Ltd.

  公开号：EP3241552A1

  公开（公告）日：2017-11-08

  A method for inhibiting a lipid metabolism disorder of a warm-blooded animal is provided. The method includes administering a pharmaceutical composition including a phosphodiesterase-5 (PDE-5) inhibitor and a Statin analogue to the warm-blooded animal suffering from the lipid metabolism disorder.

  提供了一种抑制温血动物脂质代谢紊乱的方法。该方法包括向患有脂质代谢紊乱的温血动物施用包括磷酸二酯酶-5（PDE-5）抑制剂和他汀类似物的药物组合物。
• Targeting cGMP-related phosphodiesterases to reduce cyst formation in cystic kidney disease, and related materials and methods
  申请人：Indiana University Research and Technology Corporation

  公开号：US10456404B2

  公开（公告）日：2019-10-29

  Described herein is the identification of cGMP-specific phosphodiesterase upregulation in cystic kidney diseases. Also described is the use of cGMP-specific phosphodiesterase inhibitors for preventing the progression and/or treatment of cystic kidney diseases. Other aspects described provide medicaments for preventing the progression and/or treating cystic kidney diseases, and methods of diagnosing cystic kidney disease.

  本文描述了囊性肾病中 cGMP 特异性磷酸二酯酶上调的鉴定。还描述了使用 cGMP 特异性磷酸二酯酶抑制剂预防和/或治疗囊性肾病的方法。所描述的其他方面提供了用于预防囊性肾脏疾病进展和/或治疗的药物，以及诊断囊性肾脏疾病的方法。
• COMPOUNDS IN THE FORM OF HOMODIMERIC OR HETERODIMERIC PRODRUGS; PROCESS FOR OBTAINING THESE PRODRUGS AND THEIR ACCEPTABLE PHARMACEUTICAL SALTS AND USE OF COMPOUNDS IN THE TREATMENT OF PHOSPHODIESTERASES-MEDIATED DISEASES OR DYSFUNCTION
  申请人：Cristália Produtos Químicos Farmacêuticos Ltda.

  公开号：EP1315729B1

  公开（公告）日：2008-01-09
• COMPOSITIONS AND METHODS OF TREATING PULMONARY HYPERTENSION
  申请人：Gilead Sciences, Inc.

  公开号：EP2637664A2

  公开（公告）日：2013-09-18
• NOVEL COMPOSITION FOR THE TREATMENT OF CYSTIC FIBROSIS
  申请人：SciPharm SàRL

  公开号：EP2672957A1

  公开（公告）日：2013-12-18